· Event impact
Viking, AbbVie poised for obesity drug market growth.
Transmission path
Companies with promising drug candidates in the rapidly expanding obesity market can capture significant market share, driving revenue growth and stock performance as clinical trials progress and regulatory approvals are sought.
Market mechanism
Companies with promising drug candidates in the rapidly expanding obesity market can capture significant market share, driving revenue growth and stock performance as clinical trials progress and regulatory approvals are sought.
Extended read
The obesity drug market is forecast to grow substantially, potentially reaching $100 billion by the end of the decade. While Eli Lilly and Novo Nordisk currently dominate, Viking Therapeutics and AbbVie are identified as companies with strong growth potential. Viking Therapeutics is progressing with VK-2735, a dual GLP-1/GIP receptor agonist, which is currently in phase 3 clinical trials. AbbVie is also developing its own GLP-1 receptor agonist, ABBV-624, which is in phase 2 trials. Successful clinical development and market entry for these drugs could lead to significant revenue streams and increased valuation for both companies, challenging the existing market leaders.
Exposed assets
VKTX · ABBV
Continuous event tracking, options routing, and portfolio overlap for this event and the assumptions it moves live inside Market Ontology. Start a trial →